- CNS involvement in DM1 is well established; a dedicated protocol for cognitive assessment and CNS biomarker collection is lacking.
- With disease modifying therapies crossing the blood-brain barrier, mechanistically relevant neuropsychological probes and reliable biomarkers are urgently required.
- The DMCRN workshop (Sept 2024) reviewed CNS manifestations, neuropsychological assessments, and radiological biomarkers to harmonise CNS assessment pathways.
J Neuromuscul Dis. 2026 Nov 19:22143602261503402. doi: 10.1177/22143602261503402. Online ahead of print.
ABSTRACT
Myotonic Dystrophy Type 1 (DM1) is an autosomal dominant, repeat expansion, progressive multisystem disorder. While central nervous system (CNS) involvement has been well established, a consensus on a dedicated protocol to assess cognitive function and collect CNS biomarkers is still lacking in this disease. In the era of disease-modifying therapies that cross the blood-brain barrier (BBB), availability of mechanistically relevant neuropsychological probes and reliable biomarkers of DM1 pathology is no longer deferrable. Consequently, to better define and harmonize a CNS assessment pathway, the Myotonic Dystrophy Clinical Research Network (DMCRN) convened a workshop entitled ”Myotonic Dystrophy CNS Workshop” in September 2024. Presenters described the protean manifestations of CNS involvement in DM1, shared data about neuropsychological assessments available with cross-fertilization from other neurological and neurodegenerative diseases and discussed existing data and future perspectives on CNS radiological biomarkers.
PMID:43056362 | DOI:10.1177/22143602261503402
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

